» Articles » PMID: 23837881

Surgical Management and Perioperative Morbidity of Patients with Primary Borderline Ovarian Tumor (BOT)

Overview
Journal J Ovarian Res
Publisher Biomed Central
Date 2013 Jul 11
PMID 23837881
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Surgery is the cornerstone for clinical management of patients with borderline ovarian tumors (BOT). As these patients have an excellent overall prognosis, perioperative morbidity is the critical point for decision making when the treatment strategy is developed and the primary surgical approach is defined.

Methods: Clinical and surgical parameters of patients undergoing surgery for primary BOT at our institutions between 1993 and 2008 were analyzed with regard to perioperative morbidity depending on the surgical approach (laparotomy vs. laparoscopy).

Results: A total of 105 patients were analyzed (44 with primary laparoscopy [42%], 61 with primary laparotomy [58%]). Complete surgical staging was achieved in 33 patients at primary surgical approach (31.4%) frequently leading to formal indication of re-staging procedures. Tumor rupture was significantly more frequent during laparoscopy compared to laparotomy (29.5% vs. 13.1%, p = 0.038) but no other intraoperative complications were seen in laparoscopic surgery in contrast to 7 of 61 laparotomies (0% vs. 11.5%, p = 0.020). Postoperative complication rates were similar in both groups (19.7% vs. 18.2%, p = 0.848).

Conclusions: Irrespective of the surgical approach, surgical management of BOT has acceptable rates of perioperative complications and morbidity. Choice of initial surgical approach can therefore be made independent of complication-concerns. As the recently published large retrospective AGO ROBOT study observed similar oncologic outcome for both approaches, laparoscopy can be considered for staging of patients with BOT if this appears feasible. An algorithm for the surgical management of BOT patients has been developed.

Citing Articles

Molecular landscape of borderline ovarian tumours: A systematic review.

Sadlecki P, Walentowicz-Sadlecka M Open Med (Wars). 2024; 19(1):20240976.

PMID: 38859878 PMC: 11163159. DOI: 10.1515/med-2024-0976.


The challenging management of borderline ovarian tumors (BOTs) in women of childbearing age.

Della Corte L, Mercorio A, Serafino P, Viciglione F, Palumbo M, De Angelis M Front Surg. 2022; 9:973034.

PMID: 36081590 PMC: 9445208. DOI: 10.3389/fsurg.2022.973034.


Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus.

Reichenbach J, Schmoeckel E, Mahner S, Trillsch F J Ovarian Res. 2021; 14(1):89.

PMID: 34233728 PMC: 8265084. DOI: 10.1186/s13048-021-00839-4.


Unilateral cystectomy and serous histology are associated with relapse in borderline ovarian tumor patients with fertility-sparing surgery: a systematic review and meta-analysis.

Li N, Ming X, Li Z Arch Gynecol Obstet. 2020; 302(5):1063-1074.

PMID: 32748055 DOI: 10.1007/s00404-020-05716-x.


Borderline ovarian tumours: management in the era of fertility-sparing surgery.

Maramai M, Barra F, Valenzano Menada M, Stigliani S, Moioli M, Costantini S Ecancermedicalscience. 2020; 14:1031.

PMID: 32419843 PMC: 7221127. DOI: 10.3332/ecancer.2020.1031.


References
1.
Sherman M, Mink P, Curtis R, Cote T, Brooks S, Hartge P . Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer. 2004; 100(5):1045-52. DOI: 10.1002/cncr.20080. View

2.
Gultekin E, Gultekin O, Cingillioglu B, Sayhan S, Sanci M, Yildirim Y . The value of frozen section evaluation in the management of borderline ovarian tumors. J Cancer Res Ther. 2012; 7(4):416-20. DOI: 10.4103/0973-1482.92005. View

3.
. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009; 105(1):3-4. DOI: 10.1016/j.ijgo.2008.12.015. View

4.
Harter P, Hilpert F, Mahner S, Kommoss S, Heitz F, Pfisterer J . Prognostic factors for complete debulking in first- and second-line ovarian cancer. Int J Gynecol Cancer. 2009; 19 Suppl 2:S14-7. DOI: 10.1111/IGC.0b013e3181bffb3f. View

5.
du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C . Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer. 2013; 49(8):1905-14. DOI: 10.1016/j.ejca.2013.01.035. View